Bornaprine

EN Texte en anglais Pas encore d'article dans ta langue : extrait en anglais.

Bornaprine (brand name Sormodrem) is a synthetic anticholinergic medication that is primarily used to treat Parkinson's disease. Additionally, bornaprine has been used to treat other disorders, including hyperhidrosis. Bornaprine was first synthesized in 1960 by the German scientist H Haas, under the name Kr 399. Additional tests revealed that bornaprine was significantly more effective than nicotine at antagonizing choline. Because of its anticholinergic effects, it was intended to help with the symptoms of Parkinson's. Early clinical trials with Parkinsonian patients (completed in Germany), showed that bornaprine was successful at treating many of the key side-effects of Parkinson's including akinesia, language, tremors, and psychological symptoms. Bornaprine is an antimuscarinic agent that nonselectively antagonizes muscarinic acetylcholine receptors, M1 and M2. Bornaprine has been characterized as a very potent anticholinergic medication and further clinical trials have indicated its effectiveness at treating parkinsonian tremors. Bornaprine also has a pa2 value (affinity of antagonist for receptor) of 7.27 ± 0.21 indicating a high potency. Bornaprine is successfully absorbed into the plasma of humans within 1–2 hours after an oral dose.